Symptomatic treatments for moderate to severe Alzheimer's disease are approved in the United States and include the acetylcholinesterase inhibitor donepezil and the glutamate receptor antagonist memantine. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.